Margaret Gatti-Mays, MD MPH

drgattimays.bsky.social

22 October 2025 00:41

📎Jhavari et al. Imlunestrant with or without Abemaciclib in Advanced Breast Cancer. NEJM. 2025 Link to Trial: www.nejm.org/doi/full/10....

Margaret Gatti-Mays, MD MPH

drgattimays.bsky.social

22 October 2025 00:41

📎 Kornblum et al. Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Neg Metastatic Breast Cancer Resistant to AI Therapy JCO. 2018 Link to Trial: pubmed.ncbi.nlm.nih.gov/29664714/

Margaret Gatti-Mays, MD MPH

drgattimays.bsky.social

22 October 2025 00:41

14/18 #TumorBoardTuesday 👩🏻‍🏫Mini Tweetorial 9🏫 📰 Breaking news! 🔊 evERA study (#ESMO2025) 🔎 Phase III, randomized trial (NCT05306340) 👩‍🦳 Metastatic HR+/HER2- ✅ Previous tx w/ CDK4/6i + ET 💊 Giredestrant is a novel, nonsteroidal oral SERD 🚫 NOT FDA approved as of today

Margaret Gatti-Mays, MD MPH

drgattimays.bsky.social

22 October 2025 00:39

🔍Evaluation of acquired mutations at progression will help to direct therapy options 📝Tissue-based assays or plasma-based assays (ctDNA) can be used ☝️Some alterations ->better detected by tissue-based assays like homozygous PTEN loss or TMB-H. ☝️Liquid assays --> tumor heterogeneity more accurately

Margaret Gatti-Mays, MD MPH

drgattimays.bsky.social

22 October 2025 00:39

2/18 #TumorBoardTuesday 👩🏻‍🏫Mini Tweetorial 1🏫 Actionable Mutations in 2L mER+/HER2- BC 🧬Several actionable mutations in 2L+ mBC: ESR1, PIK3CA, AKT, PTEN, BRCA (germline, somatic) 🔍Evaluation of acquired mutations at progression will help to direct therapy options